Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATG-101 |
Synonyms | |
Therapy Description |
ATG-101 is a tetravalent bispecific antibody targeting PD-L1 (CD274) and TNFRSF9 (4-1BB), which activates TNFRSF9 (4-1BB) signaling and blocks PD-1/PD-L1 interaction, potentially leading to an enhanced antitumor immune response and inhibition of tumor growth (PMID: 38501978). |